ALNY at a glance
Alnylam Pharmaceuticals (ALNY, SEC CIK 1178670) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33.
- As of June 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Alnylam Pharmaceuticals (ALNY) shares worth $18.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by SUPRAN BRYAN on October 2, 2026 of 1,758 shares at $226.88 per share.
- In the last 90 days, ALNY insiders reported 0 open-market purchases ($0) and 1 open-market sale ($399K) on Form 4, a net sale of $399K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.7B
- +65.2% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$399K
- 13F holders
- 39 funds
- $18.0B · +1 vs prior quarter
- Latest 8-K
- Jul 30, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Achieved first profitability in 2025 with net product revenues approx. $3.0B, primarily from TTR franchise growth
- Initiated Phase 3 trials in 2025 for nucresiran (next-gen TTR silencer) and zilebesiran (hypertension), emphasizing late-stage pipeline expansion
- Strategic focus on Alnylam 2030: 10 tissue types, 40+ clinical programs, 30% revenues in R&D, 25%+ CAGR, targeting two blockbusters beyond TTR
- Net product revenues up 81% YoY to $2.99B driven by AMVUTTRA growth (+138% to $2.31B), offset by ONPATTRO decline (-32% to $173M)
- Paid $1.15B to repurchase convertible notes in 2025; raised $645.7M from 0.00% Convertible Senior Notes due 2028 issuance
Risk Factors
- Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price
- Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses
- Operational reliance on third-party manufacturing and clinical trial partners to supply and develop AMVUTTRA and other products
- Market disruption risk from generic competition and emerging therapies targeting ATTR-CM and hATTR-PN indications
- Financial risk tied to royalty sale of Leqvio with $1.00B sales threshold by 12/31/2029 impacting future royalty retention percentages
AI summary of the ALNY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- AMVUTTRA revenue $1.01B; ONPATTRO $18.5M; GIVLAARI $89.8M; OXLUMO $52.1M in Q2 2026
- Best product AMVUTTRA at $1.01B; lowest product ONPATTRO at $18.5M
- 2028 Notes issuance $661.3M; capped-call payment $35.3M; 2027 Note repurchases totaled approximately $1.16B
- Management targets 25%+ revenue CAGR and approximately 30% non-GAAP operating margin through 2030; continued significant R&D investment expected
Risk Factors
- New AMVUTTRA concentration risk triggered by FDA approval for ATTR-CM in March 2025; sales comprised significant product revenue in 2025 and six months ended June 30, 2026
- Most material commercial update: AMVUTTRA net product revenues reached $1.17 billion in Q2 2026 and $2.21 billion year-to-date
- Regulatory risk from evolving drug-pricing rules, including potential U.S. government price negotiation and most-favored-nation measures
- Competitive risk from additional ATTR-CM therapies or generic competing products reducing AMVUTTRA adoption and reimbursement
- Financial risk from $3.31 billion in cash, equivalents and marketable securities exposed to credit, liquidity, market and interest-rate losses
AI summary of the ALNY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- July 30, 2026 earnings disclosure covers fiscal-year 2026 results
- Press release in Exhibit 99.1 contains the substantive financial results and management commentary
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 10 to 11 directors with Benjamin F. Cravatt, Ph.D. appointed through the 2028 annual meeting
- Cravatt joins the Science and Technology Committee, adding specialized scientific expertise to board oversight
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected three Class I directors, including CEO Yvonne Greenstreet, through the 2029 annual meeting
- Elliott Sigal received the weakest support, with 12,844,836 votes against his re-election
Item 2.02: Results of Operations and Financial Condition
- April 30, 2026 filing references a press release covering Alnylam’s reported results
- Detailed financial results and management commentary are contained in Exhibit 99.1
AI summaries of ALNY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALNY
Don't miss the next ALNY filing
- Alerts as it files. A push when ALNY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALNY, by share count.
- Ask anything. An AI agent that reads every ALNY filing and answers with sources.
ALNY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SUPRAN BRYAN | Sell | Oct 2, 2026 | 1,758 | $226.88 |
| Greenstreet Yvonne | A | Sep 19, 2026 | 107 | - |
| SCHULMAN AMY W | M | May 13, 2026 | 11,250 | - |
| SCHULMAN AMY W | M | May 13, 2026 | 11,250 | $70.20 |
| McLaughlin Melissa | Sell | Apr 6, 2026 | 199 | $333.94 |
| McLaughlin Melissa | Sell | Apr 6, 2026 | 56 | $320.14 |
| McLaughlin Melissa | Sell | Apr 6, 2026 | 829 | $330.46 |
| McLaughlin Melissa | Sell | Apr 6, 2026 | 909 | $329.76 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.2B | $3.7B |
| Operating Income | - | -$176.9M | $501.6M |
| Net Income | -$440.2M | -$278.2M | $313.7M |
| Op. Margin | - | -7.9% | 13.5% |
| Net Margin | - | -12.4% | 8.4% |
| Balance Sheet | |||
| Total Assets | $3.8B | $4.2B | $5.0B |
| Equity | - | $67.1M | $789.2M |
| ROE | - | -414.6% | 39.8% |
| Per Share | |||
| EPS | $-3.52 | $-2.18 | $2.33 |
| Cash Flow | |||
| Operating CF | - | -$8.3M | $524.1M |
| CapEx | $62.2M | $34.3M | $58.7M |
Source: XBRL data in Alnylam Pharmaceuticals (ALNY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALNY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 39 | $18.03B |
| Q1 2026 | 38 | $20.78B |
| Q4 2025 | 36 | $24.88B |
| Q3 2025 | 39 | $30.03B |
| Q2 2025 | 34 | $19.81B |
| Q1 2025 | 32 | $12.52B |
| Q4 2024 | 28 | $9.27B |
| Q3 2024 | 21 | $2.22B |
- BlackRock+462.8K (+4%)
- FMR LLC (Fidelity)+444.8K (+3%)
- State Street Corp+233.0K (+7%)
- Citadel Advisors LLC+167.6K (+716%)
- Goldman Sachs Group+105.4K (+22%)
- JPMorgan Chase & Co−3.65M (-58%)
- Invesco Ltd−320.8K (-8%)
- T. Rowe Price Group−283.5K (-20%)
- AQR Capital Management−185.1K (-20%)
- Millennium Management−131.9K (-29%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 267 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALNY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 7, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALNY SEC filings: frequently asked questions
Are ALNY insiders buying or selling?
In the last 90 days, Alnylam Pharmaceuticals (ALNY) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $398,855 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALNY stock?
As of June 30, 2026, the largest Alnylam Pharmaceuticals (ALNY) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($4.5 billion), BlackRock ($3.3 billion), Vanguard Portfolio Management LLC ($2.0 billion), Vanguard Capital Management LLC ($1.8 billion), Invesco Ltd ($1.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALNY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33. The figures come from the XBRL data in the 10-K.
What are the main risks in ALNY's latest 10-K?
In the 10-K filed February 12, 2026, Alnylam Pharmaceuticals (ALNY) flagged: Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price. Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses. (AI summary of the Risk Factors section.)
What did ALNY report in its latest 8-K?
Alnylam Pharmaceuticals (ALNY) filed an 8-K on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). July 30, 2026 earnings disclosure covers fiscal-year 2026 results.
What are the latest ALNY SEC filings?
Alnylam Pharmaceuticals (ALNY) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 30, 2026 and a Form 4 insider filing on October 6, 2026.
What is ALNY's SEC CIK number?
Alnylam Pharmaceuticals (ALNY)'s SEC Central Index Key (CIK) is 1178670. EDGAR lists every ALNY filing under that number.
Ask anything about ALNY
The research agent reads ALNY's filings, financials, insider trades and 13F holders, then answers with sources.